AARD (Aardvark Therapeutics) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AARD Aardvark Therapeutics Inc AARD
12 GF Score
Price $7.19
! 1 Warning Sign
View Full Analysis

What is Aardvark Therapeutics Short-term investments?

Short-term investments only applies to insurance companies.

AARD
12GF Score
Aardvark Therapeutics Inc AARD
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aardvark Therapeutics Business Description

Address 4370 La Jolla Village Drive, Suite 1050, San Diego, CA, USA, 92122
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
12GF Score

Get the complete analysis for AARD

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.19
Price